Commodore Capital LBRX Position
Active4-Fund ConvergenceCommodore Capital held their position in LB PHARMACEUTICALS INC (LBRX) in Q4 2025, holding $33.4M worth of shares across 1,500,000 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
LBRX is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for LB-102 (50 mg tablet) in 440 days (Jun 30, 2027), making the timing of Commodore's position particularly relevant.
Short interest stands at 11.4% of float with 12.0 days to cover, indicating significant bearish positioning against Commodore's long thesis.
About LB PHARMACEUTICALS INC
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
Full company profile →Short Interest
11.4%
12.0 days to cover
Commodore Capital LBRX Position History
Frequently Asked Questions
Does Commodore Capital own LBRX?
Yes. As of Q4 2025, Commodore Capital holds 1,500,000 shares of LB PHARMACEUTICALS INC (LBRX) valued at $33.4M. This data comes from their SEC 13F filing.
How many hedge funds own LBRX?
4 specialist biotech hedge funds currently hold LBRX, including Deep Track Capital, RA Capital Management, Baker Bros. Advisors. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Commodore Capital first buy LBRX?
Commodore Capital's position in LBRX was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Commodore Capital's LBRX position increasing or decreasing?
Commodore Capital held their LBRX position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
LBRXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Commodore CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →